| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cef4f341fe4f2caf061611a818576e40 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-227
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 |
| filingDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0f1d474a2c90649f077f87caae2d22c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_faccc8103fc377598667e8009b04a379
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb5b142cd14c3899221ac21b0379f620
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36846261cb4c739262c38c3ea4c379c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_203b977a0ada242871edf679c614cef7 |
| publicationDate |
2015-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2828242-A1 |
| titleOfInvention |
NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. |
| abstract |
The present invention is directed to novel polymorphic crystal forms of a 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisylate. The invention is also directed to pharmaceutical compositions comprising said polymorphic crystal forms, methods of using them to treat respiratory diseases associated with beta2 adrenergic receptor activity and a process for preparing such polymophic crystal forms. |
| priorityDate |
2012-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |